What can you expect at UEGW?

		Your Q1 2025 BIKTARVY® newsletter from the Global team

IN THIS ISSUE We did. A summary of what has been happening this quarter We can. A spotlight on local initiatives and their contributions to our success We did. A sneak peek at what to expect from the Global team next quarter

This quarter the focus is on: INSPIRE ACTION

Building on the momentum of our past achievements, we’ve used valuable insights from HCPs and people with HIV to reinforce our SWITCH and STAY narratives and solidify our Treatment Selection for Long-Term Success assets. These resources are designed to INSPIRE ACTION and support more people than ever before on their journey to Long-Term Success. We are proud to adopt ‘WE DID, WE CAN, WE WILL’ as our internal theme for 2025, a powerful reminder that every success fuels further innovation and progress. Let’s continue inspiring action, united in our vision, as we take our next steps in 2025.

WE DID

In Q1, we’ve rolled out resources with a person-centred approach.

BMJ-hosted BIKTARVY® Microsite We’ve updated the BIKTARVY® microsite to align with our Global eDA. A brand new ‘Data updates’ page is now live, with regular updates to follow.

Global STAY Strategic Guidance Building on the START/SWITCH guidance delivered in Q4, we’re excited to release STAY guidance including patient profiles, and guidance on the recommended in-call approach.

Veeva Approved Content Sheets: One-page summaries, distilling the latest BIKTARVY® data to support START/SWITCH/STAY conversations. Click below to discover:

2025 Global Content Calendar: A Global calendar outlining material delivery timelines. Don’t miss the first tab, where you’ll find our internal manifesto – our promise to you for the year ahead!

CROI Renal eDA page: A new renal safety page leveraging new data from CROI – reaffirming BIKTARVY®’s role as a trusted treatment option for a broad range of people with HIV.

WE CAN

This quarter, the spotlight is on... The United States

The U.S. team kicked off 2025 with a National Sales Meeting. We are driving key initiatives that position BIKTARVY® for continued success, which include:

Optimising HCP impact with Person-First Engagement (PFE) The PFE approach tailors HCP interactions to four distinct HCP personas based on deep data insights. This ensures more relevant and personalised conversations, maximising sales call impact and reinforcing confidence in BIKTARVY®.

Driving growth through differentiation and targeted strategies We will continue on the offensive with our efforts to: •   Dominate START, Accelerate SWITCH, and Maximise STAY Drive new initiations, patient retention, and conversions by reinforcing the key differentiators of BIKTARVY® •   Close the 6% share gap in the 50+ population Differentiate the breadth of BIKTARVY® clinical trial data for the growing 50+ population, boosting prescriber confidence •   Leverage SOLAR study insights Highlight the impact of individual and community resistance while reinforcing the clinical profile of BIKTARVY®, including 0 treatment-emergent resistance in clinical trials

With a successful National Sales Meeting kickoff, the U.S. team has already made strides in 2025. A fantastic start to what promises to be an impactful year ahead! Congratulations to the U.S. team on these exciting plans!

WE CAN

As we move into Q2, our focus will be to INSPIRE IMPACT, ensuring that our efforts drive progress and create meaningful change. We look forward to hearing how these efforts inspire impact in your region. Expert Summit Event 4th & 5th April Supporting engagement with the next generation of HCPs highlighting the importance of treatment selection in achieving Long-Term Success. Treatment Selection for Long-Term Success Microsite An interactive and engaging microsite highlighting the treatment considerations for Long-Term Success, told through emotive patient stories as well as clinical data. Strengthen our Messaging for 2025 As we continue to strengthen our START/SWITCH/STAY messaging, we’re diving deep into market research on HCP behaviour. This will provide us with valuable insights to shape our messaging strategy moving forward.

Thank you for your continued dedication to the BIKTARVY® Global team. With your help, we’re dedicated to taking a person- centred approach to support people with HIV for today, tomorrow, and the days to come. Stay tuned for more exciting updates in Q2!

Internal use only